233 related articles for article (PubMed ID: 29685424)
1. Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm.
Bair SM; Mato A; Svoboda J
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):380-391. PubMed ID: 29685424
[TBL] [Abstract][Full Text] [Related]
2. Relapse of Hodgkin lymphoma after autologous hematopoietic cell transplantation: A current management perspective.
Iqbal M; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):95-103. PubMed ID: 32603659
[TBL] [Abstract][Full Text] [Related]
3. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.
Grosser R; Cherkassky L; Chintala N; Adusumilli PS
Cancer Cell; 2019 Nov; 36(5):471-482. PubMed ID: 31715131
[TBL] [Abstract][Full Text] [Related]
4. [Not Available].
Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
[TBL] [Abstract][Full Text] [Related]
5. Current and future immunotherapeutic approaches in Hodgkin lymphoma.
Bröckelmann PJ; Borchmann P; Engert A
Leuk Lymphoma; 2016 Sep; 57(9):2014-24. PubMed ID: 27243940
[TBL] [Abstract][Full Text] [Related]
6. Development of adaptive immune effector therapies in solid tumors.
Comoli P; Chabannon C; Koehl U; Lanza F; Urbano-Ispizua A; Hudecek M; Ruggeri A; Secondino S; Bonini C; Pedrazzoli P;
Ann Oncol; 2019 Nov; 30(11):1740-1750. PubMed ID: 31435646
[TBL] [Abstract][Full Text] [Related]
7. The emerging role of immune checkpoint based approaches in AML and MDS.
Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
[TBL] [Abstract][Full Text] [Related]
8. Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma.
Calabretta E; d'Amore F; Carlo-Stella C
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31694167
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of immunotherapy for prostate cancer.
Noguchi M; Koga N; Igawa T; Itoh K
Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
[TBL] [Abstract][Full Text] [Related]
10. Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors.
Epperla N; Hamadani M
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):247-253. PubMed ID: 34889401
[TBL] [Abstract][Full Text] [Related]
11. Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma.
Choi Y; Diefenbach CS
Curr Oncol Rep; 2020 Jan; 22(1):6. PubMed ID: 31981025
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance and new therapies in colorectal cancer.
Van der Jeught K; Xu HC; Li YJ; Lu XB; Ji G
World J Gastroenterol; 2018 Sep; 24(34):3834-3848. PubMed ID: 30228778
[TBL] [Abstract][Full Text] [Related]
13. [Checkpoint inhibitors in Hodgkin lymphoma].
Sasse S; Momotow J; Engert A
Internist (Berl); 2020 Jul; 61(7):660-668. PubMed ID: 32462248
[TBL] [Abstract][Full Text] [Related]
14. Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide.
Paulson KG; Bhatia S
J Natl Compr Canc Netw; 2018 Jun; 16(6):782-790. PubMed ID: 29891528
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.
Pianko MJ; Moskowitz AJ; Lesokhin AM
Clin Cancer Res; 2018 Mar; 24(5):1002-1010. PubMed ID: 28899972
[TBL] [Abstract][Full Text] [Related]
16. Outlook: Immunotherapy in Gastrointestinal Carcinoma - Innovative Strategies.
Moehler M; Göpfert K; Lenz HJ
Oncol Res Treat; 2018; 41(5):313-315. PubMed ID: 29705792
[TBL] [Abstract][Full Text] [Related]
17. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.
Carella AM; Corradini P; Mussetti A; Ricardi U; Vitolo U; Viviani S
Ann Hematol; 2018 Aug; 97(8):1301-1315. PubMed ID: 29802458
[TBL] [Abstract][Full Text] [Related]
18. Immune and Cell Therapy in Non-Hodgkin Lymphoma.
Merryman RW; Houot R; Armand P; Jacobson C
Cancer J; 2020; 26(3):269-277. PubMed ID: 32496460
[TBL] [Abstract][Full Text] [Related]
19. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
20. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
Su CT; Ye JC
J Hematol Oncol; 2021 Jul; 14(1):115. PubMed ID: 34301270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
